# Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

> **NCT01013675** · PHASE2 · COMPLETED · sponsor: **Abbott Biologicals** · enrollment: 622 (actual)

## Conditions studied

- Influenza Vaccines

## Interventions

- **BIOLOGICAL:** Influenza Vaccine
- **BIOLOGICAL:** Influenza Vaccine

## Key facts

- **NCT ID:** NCT01013675
- **Lead sponsor:** Abbott Biologicals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 622 (ACTUAL)
- **Last updated:** 2011-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01013675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01013675, "Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01013675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*